Navigation Links
Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
Date:3/28/2008

TOKYO and WOODCLIFF LAKE, N.J., March 28 /PRNewswire/ -- Eisai Co., Ltd. and its U.S. subsidiary Eisai Inc. (collectively "Eisai") today announced that the United States District Court for the District of New Jersey has ruled in Eisai's favor with respect to Eisai's motion for a preliminary injunction in its patent infringement lawsuit against Teva Pharmaceuticals and its division Gate Pharmaceuticals (collectively "Teva"), concerning Aricept(R) (generic name: donepezil hydrochloride tablets).

As previously announced, Eisai filed the infringement actions in December 2005 contesting Teva's submission of an abbreviated new drug application (ANDA) to the FDA for Aricept(R).

"We are pleased with the court's preliminary injunction decision to prevent the sale of Teva's generic product before the expiration of the donepezil composition of matter patent," said Mr. Hajime Shimizu, Chairman & CEO of Eisai Corporation of North America and Eisai Inc. "We will continue to actively protect our intellectual property throughout the world."

Aricept(R), an acetylcholinesterase inhibitor developed by Eisai Co., Ltd. in Japan, increases the concentration of acetylcholine, a neurotransmitter, in the brain. Aricept(R) was launched in the United States in 1997 and is indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer's type. In the United States, Eisai Inc. copromotes Aricept(R) with Pfizer Inc.

About Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai's corporate human health care (hhc) mission is to give first thought to patients and their families, and to increase the benefits that health care provides. The company believes that increasing patient satisfaction through the development of innovative new medicines exemplifies its important mission. For more information about Eisai Co., Ltd., please visit '/>"/>

SOURCE Eisai Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Eisai/Pfizers Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimers Disease
2. Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
3. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
4. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
5. Genta Granted Extension to Achieve Compliance with NASDAQ Listing Requirements
6. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
7. Kiwa Bio-Tech New Bio-Fertilizer Product Granted Initial Fertilizer Registration Certificate By Ministry of Agriculture of the PRC
8. Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
9. Odyssey Thera Granted U.S. Patent for Animal Imaging
10. ISTO Technologies Granted Key Patent for Cartilage Cell Expansion by the United States Patent Office
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):H1N1 influenza adopted novel strategy to move from birds to humans 2H1N1 influenza adopted novel strategy to move from birds to humans 3H1N1 influenza adopted novel strategy to move from birds to humans 4Superior offspring without genetic modification 2Study finds new relationship between gene duplication and alternative splicing in plants 2Study finds new relationship between gene duplication and alternative splicing in plants 3Palomar to Commercialize FDA Cleared Over The Counter Home Use Wrinkle Treatment Laser Device Without Johnson 26amp 3B Johnson 5536 1Palomar to Commercialize FDA Cleared Over The Counter Home Use Wrinkle Treatment Laser Device Without Johnson 26amp 3B Johnson 5536 2Palomar to Commercialize FDA Cleared Over The Counter Home Use Wrinkle Treatment Laser Device Without Johnson 26amp 3B Johnson 5536 3Palomar to Commercialize FDA Cleared Over The Counter Home Use Wrinkle Treatment Laser Device Without Johnson 26amp 3B Johnson 5536 4Palomar to Commercialize FDA Cleared Over The Counter Home Use Wrinkle Treatment Laser Device Without Johnson 26amp 3B Johnson 5536 5Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 1Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 2Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 3Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 4Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 5Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 6Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 7Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 8Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 9Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 10Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 11Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 12Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 13Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 14Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 15Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 16Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 17Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 18Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 19Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 20Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 21Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 22Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 23Reportlinker Adds Global Top 10 Chemical Companies Industry Financial and SWOT Analysis 5530 24Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 1Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 2Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 3Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 4Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 5Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 6Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 7Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 8Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 9Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 10Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014 3A Policy environment market structure competitive landscape growth oppo 5528 11